Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Smoldering Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Rochester, Rochester, New York, United States
Contact: Study coordinator (Jodi Lipof) · jodi_lipof@urmc.rochester.edu

Study leads

Jodi Lipof
Principal Investigator
University of Rochester

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

High-risk Smoldering Multiple Myeloma · Smoldering Multiple Myeloma · Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Denver, United States · Boston, United States

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance (MGUS) · Smoldering Multiple Myeloma (SMM)

Abroad (travel likely)RecruitingPHASE2

Baltimore, United States · Boston, United States

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Miami, United States

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Multiple Myeloma · Smoldering Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Oslo, Norway